Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects

Fan YAO; Xin YIN

doi:10.3969/j.issn.1001-5256.2022.11.039

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2632-2635

PDF( 2121 KB)

Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects

DOI: 10.3969/j.issn.1001-5256.2022.11.039

Fan YAO,
Xin YIN^{,
,}

Department of Liver Oncology, Zhongshan Hospital, Fudan University, Shanghai 200030, China

Research funding:

National Natural Science Foundation of China (81972889)

More Information

Corresponding author: YIN Xin, yin.xin@zs-hospital.sh.cn(ORCID: 0000-0002-9892-7845)
Received Date: 2022-04-01
Accepted Date: 2022-05-09
Published Date: 2022-11-20

Abstract

Abstract

With the application of immune checkpoint inhibitors in various solid tumors, problems such as drug resistance and poor response gradually occur, and therefore, in order to better improve the prognosis of patients, it is urgent to explore better immunotherapy regimens. This article introduces an emerging immune checkpoint TIGIT and its high-affinity ligand CD155 and summarizes the regulatory effect of the TIGIT/CD155 pathway on the immune microenvironment of liver cancer and the application of inhibitors targeting TIGIT in immunotherapy for liver cancer. It is believed that TIGIT/CD155 can change the immune microenvironment of liver cancer through immune cells and stromal cells, thereby causing immune escape and worsening of disease conditions. The analysis shows that the targeted therapy for TIGIT will become a new direction for the development of liver cancer therapy and play an important role in combined immunotherapy.
- Liver Neoplasms,
- Immunosuppressive Agents,
- Tumor Microenvironment

FullText(HTML)

References(27)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
[3]	WEI JY, SUN W, LIU XM, et al. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. J Clin Hepatol, 2020, 36(10): 2320-2324. DOI: 10.3969/j.issn.1001-5256.2020.10.035. 魏建莹, 孙巍, 刘晓民, 等. 肝细胞癌的靶向及免疫治疗进展[J]. 临床肝胆病杂志, 2020, 36(10): 2320-2324. DOI: 10.3969/j.issn.1001-5256.2020.10.035.
[4]	QIN XY, LIU YY, KANG Q. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. Ogran Transplant, 2022, 13(2): 271-276. DOI: 10.3969/j.issn.1674-7445.2022.02.018. 秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗[J]. 器官移植, 2022, 13(2): 271-276. DOI: 10.3969/j.issn.1674-7445.2022.02.018.
[5]	ZONGYI Y, XIAOWU L. Immunotherapy for hepatocellular carcinoma[J]. Cancer Lett, 2020, 470: 8-17. DOI: 10.1016/j.canlet.2019.12.002.
[6]	SADEGHI RAD H, MONKMAN J, WARKIANI ME, et al. Understanding the tumor microenvironment for effective immunotherapy[J]. Med Res Rev, 2021, 41(3): 1474-1498. DOI: 10.1002/med.21765.
[7]	GUAN QT, HAN MW, XI D. Research progress of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma[J]. J Inter Intens Med, 2021, 27(3): 187-192. DOI: 10.11768/nkjwzzzz20210303. 关倩婷, 韩美文, 习东. 免疫检查点抑制剂治疗肝细胞癌的研究进展[J]. 内科急危重症杂志, 2021, 27(3): 187-192. DOI: 10.11768/nkjwzzzz20210303.
[8]	YU X, HARDEN K, GONZALEZ LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J]. Nat Immunol, 2009, 10(1): 48-57. DOI: 10.1038/ni.1674.
[9]	DUAN X, LIU J, CUI J, et al. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma[J]. Mol Med Rep, 2019, 20(4): 3773-3781. DOI: 10.3892/mmr.2019.10641.
[10]	LUPO KB, MATOSEVIC S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma[J]. J Hematol Oncol, 2020, 13(1): 76. DOI: 10.1186/s13045-020-00913-2.
[11]	ZHANG J, ZHU Y, WANG Q, et al. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis[J]. Urol Oncol, 2020, 38(2): 41. DOI: 10.1016/j.urolonc.2019.07.006.
[12]	SUN H, HUANG Q, HUANG M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma[J]. Hepatology, 2019, 70(1): 168-183. DOI: 10.1002/hep.30347.
[13]	DEUSS FA, WATSON GM, FU Z, et al. Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155[J]. Structure, 2019, 27(2): 219-228. e3. DOI: 10.1016/j.str.2018.10.023.
[14]	ZHANG C, WANG Y, XUN X, et al. TIGIT can exert immunosuppressive effects on CD8⁺ T cells by the CD155/TIGIT signaling pathway for hepatocellular carcinoma in vitro[J]. J Immunother, 2020, 43(8): 236-243. DOI: 10.1097/CJI.0000000000000330.
[15]	LIU X, LI M, WANG X, et al. PD-1⁺ TIGIT⁺ CD8⁺ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2019, 68(12): 2041-2054. DOI: 10.1007/s00262-019-02426-5.
[16]	ZONG L, PENG H, SUN C, et al. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice[J]. Nat Commun, 2019, 10(1): 221. DOI: 10.1038/s41467-018-08096-8.
[17]	SHI H, CHI H. Metabolic control of treg cell stability, plasticity, and tissue-specific heterogeneity[J]. Front Immunol, 2019, 10: 2716. DOI: 10.3389/fimmu.2019.02716.
[18]	TREHANPATI N, VYAS AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer[J]. Scand J Immunol, 2017, 85(3): 175-181. DOI: 10.1111/sji.12524.
[19]	JOLLER N, LOZANO E, BURKETT PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses[J]. Immunity, 2014, 40(4): 569-581. DOI: 10.1016/j.immuni.2014.02.012.
[20]	SUN C, XU J, HUANG Q, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer[J]. Oncoimmunology, 2017, 6(1): e1264562. DOI: 10.1080/2162402X.2016.1264562.
[21]	YU L, LIU X, WANG X, et al. TIGIT⁺ TIM-3⁺ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10(1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
[22]	YIN Z, DONG C, JIANG K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma[J]. J Hematol Oncol, 2019, 12(1): 101. DOI: 10.1186/s13045-019-0782-x.
[23]	INOUE T, ADACHI K, KAWANA K, et al. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor[J]. Int J Oncol, 2016, 49 (4) : 1297-1304. DOI: 10.3892/ijo.2016.3631.
[24]	HORVATH L, PIRCHER A. ASCO 2020 non-small lung cancer (NSCLC) personal highlights[J]. Memo, 2021, 14(1): 66-69. DOI: 10.1007/s12254-020-00673-2.
[25]	LI D. Research progress of immune checkpoint PD-1/PD-L1 inhibitor resistance mechanism and treatment strategy[J]. China & Foreign Medical Treatment, 2021, 40(17): 195-198. DOI: 10.16662/j.cnki.1674-0742.2021.17.195. 李典. 免疫检查点PD-1/PD-L1抑制剂耐药机制与治疗策略的研究进展[J]. 中外医疗, 2021, 40(17): 195-198. DOI: 10.16662/j.cnki.1674-0742.2021.17.195.
[26]	HUNG AL, MAXWELL R, THEODROS D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM[J]. Oncoimmunology, 2018, 7(8): e1466769. DOI: 10.1080/2162402X.2018.1466769.
[27]	HAN HS, JEONG S, KIM H, et al. TOX-expressing terminally exhausted tumor-infiltrating CD8⁺ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer[J]. Cancer Lett, 2021, 499: 137-147. DOI: 10.1016/j.canlet.2020.11.035.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (563) PDF downloads(72)

Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects

DOI: 10.3969/j.issn.1001-5256.2022.11.039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects

DOI: 10.3969/j.issn.1001-5256.2022.11.039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content